A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Latest Information Update: 25 Oct 2023
At a glance
- Drugs Cannabidiol (Primary)
- Indications Prader-Willi syndrome
- Focus Registrational; Therapeutic Use
- Acronyms SCOUT-015
- Sponsors Radius Health Inc.
- 05 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 02 Nov 2022 This trial has been discontinued in Sweden according to European Clinical Trials Database record.
- 03 Oct 2022 Status changed from recruiting to active, no longer recruiting.